Financial Performance - The company's operating revenue for Q3 2025 was ¥62,208,767.34, representing a year-on-year increase of 21.71%[5] - The net profit attributable to shareholders was a loss of ¥14,504,288.91, a decrease of 36.03% compared to the same period last year[5] - The basic and diluted earnings per share were both -¥0.15, reflecting a decline of 36.36% year-on-year[5] - Total revenue for the current period reached ¥168,815,578.79, an increase of 8.3% compared to ¥156,206,480.29 in the previous period[26] - The company's net loss for the current period was ¥150,416,810.44, worsening from a loss of ¥127,225,962.39 in the previous period[25] - Operating profit was recorded at -¥19,693,368.35, worsening from -¥8,934,856.80 year-over-year[27] - The total comprehensive loss attributable to the parent company was ¥23,190,848.05, compared to ¥9,419,391.96 in the previous period[27] - Basic and diluted earnings per share were both reported at -¥0.23, worsening from -¥0.09 in the previous period[28] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,406,346,517.87, an increase of 7.52% from the end of the previous year[5] - The total assets of the company reached ¥1,406,346,517.87, up from ¥1,308,019,534.65, indicating a growth of 7.5%[25] - The company's total liabilities increased to ¥383,211,232.60 from ¥276,170,069.50, reflecting a rise of 38.7%[25] Cash Flow - The net cash flow from operating activities was -100,080,517.72, a decrease of 168.43% compared to the previous period due to increased cash payments for materials and goods[14] - Cash flow from operating activities showed a net outflow of -¥100,080,517.72, compared to -¥37,283,008.94 in the previous period, indicating a deterioration in cash flow[29] - The net cash flow from investing activities improved by 91.53%, amounting to -13,981,694.93, attributed to a reduction in cash management scale[14] - Investment activities resulted in a net cash outflow of -¥13,981,694.93, an improvement from -¥165,008,241.47 in the previous period[30] - The company’s financing activities generated a net cash outflow of -¥13,514,130.23, slightly better than -¥14,533,540.86 in the previous period[30] - The cash and cash equivalents at the end of the period stood at ¥74,371,585.41, down from ¥168,931,088.84 at the end of the previous period[30] - The company's cash and cash equivalents decreased significantly to ¥83,475,584.19 from ¥217,819,411.25, a decline of 61.7%[23] Inventory and Borrowings - The company reported a significant increase in inventory, which rose by 60.72% to ¥286,478,549.84 due to acquisitions[11] - Inventory increased to ¥286,478,549.84 from ¥178,249,714.55, representing a substantial growth of 60.8%[23] - The company's short-term borrowings increased by 299.55% to ¥34,000,000.00, attributed to new company acquisitions[11] - The company's short-term borrowings surged to ¥34,000,000.00 from ¥8,509,634.00, an increase of 299.5%[24] Shareholder Information - The total number of common shareholders at the end of the reporting period was 24,382, with no preferred shareholders having restored voting rights[16] - The largest shareholder, Pan Feng, holds 25.41% of the shares, totaling 25,369,500 shares[16] - The company has a significant shareholder relationship, with Pan Feng and Zhong Wangjun being spouses, and several shareholders acting in concert[16] - The total number of restricted shares at the beginning of the period was 39,564,711, with 27,521,629 shares released from restrictions during the period[19] - The company reported a total of 12,043,082 restricted shares remaining at the end of the period[19] Research and Development - Research and development expenses decreased by 35.87% to ¥15,000,174.01, due to reduced material inputs[13] - Research and development expenses decreased to ¥15,000,174.01 from ¥23,391,037.12, a reduction of 35.7%[26] Government Subsidies - The company received government subsidies amounting to ¥693,253.82 during the reporting period, contributing to its financial performance[7] Acquisitions - The company completed the acquisition of 51% of Shandong Carbon Seeking New Materials Co., Ltd. for RMB 46.90 million, with the transaction finalized on September 15, 2025[20] - The company’s goodwill increased by 70.25% to ¥82,300,840.08, reflecting the impact of recent acquisitions[11]

Financial Performance - The company's revenue for Q3 2025 was ¥144,907,398.09, representing a decrease of 12.57% compared to the same period last year[5]. - The net profit attributable to shareholders was a loss of ¥21,783,561.40, an increase in loss of 58.05% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥23,058,299.19, which is 58.81% worse than the previous year[5]. - The company's basic earnings per share for Q3 2025 was -¥0.0628, a deterioration of 57.71% compared to the same period last year[5]. - The company's operating income for the first nine months of 2025 was ¥429,263,703.57, down 7.12% from ¥462,193,617.06 in the same period last year[10]. - Total revenue for the current period is RMB 429.26 million, a decrease of 7.1% from RMB 462.19 million in the previous period[22]. - The company reported a net profit of -107,028,427.53 yuan, compared to -172,457,181.76 yuan in the previous period, indicating an improvement of approximately 38%[23]. - Operating profit was -105,012,150.37 yuan, an improvement from -170,517,779.03 yuan year-over-year[23]. - The total comprehensive income attributable to the parent company was -97,298,376.26 yuan, compared to -158,577,188.07 yuan in the previous period, showing an improvement of about 39%[24]. - Basic earnings per share were -0.2789, an improvement from -0.4498 in the previous period[24]. Cash Flow - Cash flow from operating activities showed a significant increase of 198.95%, totaling ¥47,642,907.07 year-to-date[5]. - Cash flow from operating activities turned positive at ¥47,642,907.07, a substantial increase of 198.95% compared to the previous year, driven by organizational restructuring[11]. - The net cash flow from operating activities was 47,642,907.07 yuan, a significant recovery from -48,147,116.27 yuan in the previous period[26]. - Cash flow from investing activities improved to ¥23,094,484.86, a 120.91% increase, mainly due to the receipt of funds from the sale of a 90% stake in a pharmaceutical company[11]. - Cash flow from financing activities decreased to -¥125,735,648.52, a decline of 180.89%, resulting from reduced borrowings and increased debt repayments[11]. Assets and Liabilities - The total assets at the end of Q3 2025 were ¥2,580,324,640.17, down 7.63% from the end of the previous year[5]. - The company's cash and cash equivalents decreased to RMB 259.09 million from RMB 307.18 million, a decline of 15.6%[18]. - Total assets decreased to RMB 2.58 billion from RMB 2.79 billion, a decline of 7.6%[20]. - The company's total liabilities decreased to RMB 1.62 billion from RMB 1.72 billion, a reduction of 6.1%[20]. - The company's equity attributable to shareholders decreased to RMB 965.43 million from RMB 1.06 billion, a decline of 9.3%[20]. Research and Development - The company's R&D expenses decreased by 27.61% to ¥32,361,278.41, primarily due to reduced investment in R&D projects[10]. - The company incurred research and development expenses of 32,361,278.41 yuan, down from 44,704,949.95 yuan, representing a reduction of approximately 27%[23]. Investment and Financing - Investment income increased significantly to ¥18,799,839.12, a rise of 615.95% compared to the previous year, primarily due to the exclusion of certain pharmaceutical companies from the financial statements[11]. - The company reported investment income of 18,799,839.12 yuan, a significant recovery from a loss of -3,643,763.21 yuan in the previous period[23]. - The company reported a significant increase in short-term borrowings by 36.15%, totaling ¥468,687,948.82[10]. - Short-term borrowings increased to RMB 468.69 million from RMB 344.24 million, an increase of 36.3%[20]. Management and Strategic Initiatives - The company has implemented a "streamlined and efficient" management restructuring, leading to reduced management and sales expenses compared to the previous year[11]. - The company is focusing on market expansion and new product development as part of its strategic initiatives[11]. - The company plans to publicly transfer 90% of its subsidiary Hubei Guangji Pharmaceutical Technology Co., Ltd. at a minimum valuation of RMB 44.7856 million[15]. - Hubei Guanghua Pharmaceutical Co., Ltd. will increase its registered capital by RMB 250 million, introducing at least two strategic investors[16]. - The company completed the transfer of 90% equity in Hubei Guangji Pharmaceutical Technology Co., Ltd. on July 7, 2025[15]. Regulatory and Compliance - The company received a warning and a fine of ¥1.5 million from the China Securities Regulatory Commission for information disclosure violations[14]. Inventory and Credit - The company's inventory stock decreased by 53.40% to ¥9,893,247.00, attributed to the failure of equity incentives to meet performance conditions[10]. - The company reported a significant increase in credit impairment losses, totaling ¥1,760,428.17, up 349.08% year-on-year[11].

证券代码：301391 证券简称：卡莱特 公告编号：2025-065 卡莱特云科技股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完 整。 卡莱特云科技股份有限公司 2025 年第三季度报告 （二） 非经常性损益项目和金额 适用 □不适用 3.第三季度财务会计报告是否经过审计 □是 否 1 卡莱特云科技股份有限公司 2025 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | ...

Financial Performance - The company's operating revenue for Q3 2025 was ¥31,846,328.33, a decrease of 11.76% compared to the same period last year[5]. - Net profit attributable to shareholders reached ¥8,716,747.48, reflecting a significant increase of 48,724.30% year-on-year[5]. - The net profit after deducting non-recurring gains and losses was ¥7,053,860.31, up 444.37% from the previous year[5]. - The company reported a basic earnings per share of ¥0.0264, an increase of 26,500.00% year-on-year[5]. - The weighted average return on equity was 3.66%, up from 2.18% in the same period last year[5]. - Total operating revenue for the current period is 83,438,454.98, down from 92,417,062.87 in the previous period, representing a decrease of approximately 11.4%[20]. - The net profit for the current period is -3,149,584.02, an improvement from -8,885,815.36 in the previous period, reflecting a reduction in losses[21]. - The basic and diluted earnings per share for the current period are 0.0159, compared to -0.0255 in the previous period, showing a positive turnaround[22]. Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥841,955,975.52, representing a growth of 38.44% compared to the end of the previous year[5]. - Total assets amount to 841,955,975.52, up from 608,169,817.97 in the previous period, indicating a growth of about 38.3%[19]. - Total liabilities are 479,299,987.90, compared to 326,171,710.73 in the previous period, representing an increase of approximately 46.8%[19]. - The company's equity attributable to shareholders is 242,327,514.63, up from 237,095,180.02 in the previous period, reflecting a slight increase of about 2.0%[19]. Investments and Acquisitions - The company experienced a 16425.49% increase in trading financial assets, totaling ¥100,456,626.00 due to reclassification of other non-current financial assets[10]. - Long-term borrowings increased by 738.72% to ¥75,485,000.00, attributed to the addition of a new subsidiary[11]. - The company reported a 154.14% increase in investment income, totaling ¥5,310,324.47, primarily from trust financial products[11]. - The company initiated the sale of a 52% stake in Nanhua Peace Hospital Management (Hunan) Co., Ltd. at a base price of 19.9919 million RMB, with the transaction completed on October 21, 2025[14]. - The company acquired a 43.05% stake in Loudi Jinhong New Materials Co., Ltd. for 48.6249 million RMB and increased its investment by 30 million RMB, achieving a controlling stake of 55%[15]. - The company is planning to acquire a 51% stake in Hunan Huize Biological Pharmaceutical Technology Co., Ltd., with ongoing due diligence and negotiations[16]. Cash Flow and Expenditures - Cash flow from operating activities increased to 129,067,161.46 from 121,599,540.26 in the previous period, marking an increase of approximately 6.1%[24]. - Total cash inflow from investment activities was $110,346,204.21, down from $223,029,733.17, indicating a decrease in investment returns[26]. - Cash outflow from investment activities totaled $167,039,408.23, compared to $328,548,828.94 previously, showing a reduction in investment expenditures[26]. - Net cash flow from financing activities was -$5,344,267.76, a decrease from -$180,471,647.76, suggesting improved financing conditions[26]. - The ending cash and cash equivalents balance was $162,620,548.64, down from $214,707,973.70, indicating a decline in liquidity[26]. - Cash received from the recovery of investments was $105,000,000.00, down from $218,149,937.31, reflecting a decline in investment recoveries[25]. - Cash paid for the acquisition of fixed assets was $813,823.20, significantly lower than $16,052,536.23 in the previous period, indicating reduced capital expenditures[26]. Operational Strategy - The company has implemented multiple asset transactions and business expansion initiatives to optimize its business structure and mitigate operational risks[14]. - The company’s financial performance and strategic moves indicate a focus on enhancing core business competitiveness and exploring new profit growth points[14]. - Research and development expenses for the current period are 6,236,518.78, down from 7,034,234.69 in the previous period, indicating a decrease of approximately 11.3%[20]. Future Outlook - The company reported a total profit and net profit for 2024 expected to be negative, with operating revenue projected to be below 300 million RMB, raising investment risk concerns[14]. - The company did not undergo an audit for the third quarter financial report, which may affect investor confidence[27]. - The company plans to implement new accounting standards starting in 2025, which may impact future financial reporting[28].

Revenue and Profit - Revenue for Q3 2025 reached ¥190,511,626.17, an increase of 37.60% year-over-year, and cumulative revenue for the year-to-date is ¥650,402,071.74, up 34.60% compared to the same period last year[5] - Net profit attributable to shareholders for Q3 2025 was ¥46,566,046.69, a significant increase of 180.42% year-over-year, with year-to-date net profit at ¥127,542,147.59, up 53.20%[5] - Basic earnings per share for Q3 2025 was ¥0.14, reflecting a growth of 180.00% compared to the same quarter last year, while diluted earnings per share also stood at ¥0.14[5] - Total operating revenue for the current period reached ¥650,402,071.74, a significant increase of 34.7% compared to ¥483,199,031.40 in the previous period[18] - Net profit for the current period was ¥133,331,124.03, representing a 31.7% increase from ¥101,160,391.09 in the previous period[19] - The company reported a basic and diluted earnings per share of ¥0.38, up from ¥0.25 in the previous period[19] Cash Flow and Operating Activities - The net cash flow from operating activities for the year-to-date reached ¥218,949,128.10, a substantial increase of 493.47%[5] - The net cash flow from operating activities was ¥218,949,128.10, a turnaround from a negative cash flow of ¥55,645,041.40 in the prior period[20] - The company reported a significant increase in cash received from sales, totaling ¥608,125,559.31, which is a 53.14% increase year-over-year[9] - The company raised ¥2,000,000.00 from investment activities, a decrease from ¥80,916,016.73 in the prior period[20] Assets and Liabilities - Total assets at the end of Q3 2025 were ¥3,823,039,396.66, a decrease of 5.40% from the end of the previous year[5] - Total current assets decreased from 3,066,516,393.92 CNY to 2,865,774,175.96 CNY, a decline of approximately 6.55%[15] - Cash and cash equivalents decreased from 404,992,589.01 CNY to 264,930,164.00 CNY, a decline of approximately 34.5%[15] - Accounts receivable decreased from 1,546,239,844.83 CNY to 1,467,967,029.59 CNY, a decline of approximately 5.04%[15] - Inventory increased from 889,627,940.50 CNY to 1,002,475,786.77 CNY, an increase of approximately 12.65%[15] - Total liabilities decreased from 1,476,944,203.18 CNY to 1,132,794,333.42 CNY, a decline of approximately 23.2%[16] - Non-current assets decreased from 974,824,268.80 CNY to 957,265,220.70 CNY, a decline of approximately 1.8%[16] Shareholder Information - Total number of common shareholders at the end of the reporting period is 33,873[11] - The largest shareholder, Wang Shumin, holds 36.32% of shares, totaling 120,516,631 shares[12] - The company's equity attributable to shareholders increased to ¥2,616,502,311.10, up 4.81% from the end of the previous year[5] - The total equity attributable to shareholders of the parent company increased to ¥2,616,502,311.10 from ¥2,496,442,683.84[17] - Retained earnings increased from 1,117,792,521.89 CNY to 1,237,702,036.68 CNY, an increase of approximately 10.7%[16] Expenses and Losses - Research and development expenses for Q3 2025 were ¥67,800,446.40, a slight decrease of 1.56% compared to the same period last year[9] - The company experienced a 66.39% increase in credit impairment losses, amounting to -¥27,751,259.86, primarily due to increased provisions for bad debts[9] - The company incurred a credit impairment loss of ¥27,751,259.86, compared to a loss of ¥16,678,316.37 in the previous period[18] - Total operating costs amounted to ¥480,639,663.87, up 33.4% from ¥360,184,421.58 in the prior period[18] Other Information - The third quarter financial report of Beijing Beimo High-tech Friction Material Co., Ltd. has not been audited[22] - The new accounting standards will be implemented starting from 2025[22] - The financial report for the year of first implementation will reflect adjustments from the beginning of the year[22] - The company’s board of directors issued the report on October 24, 2025[22]

证券代码：002951 证券简称：金时科技 公告编号：2025-076 四川金时科技股份有限公司 2025 年第三季度报告 四川金时科技股份有限公司 2025 年第三季度报告 四川金时科技股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会及董事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担 个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度财务会计报告是否经过审计 □是 ☑否 一、主要财务数据 （一） 主要会计数据和财务指标 四川金时科技股份有限公司 2025 年第三季度报告 （二） 非经常性损益项目和金额 ☑适用 □不适用 | | | | 单位：元 | | --- | --- | --- | --- | | 项目 | 本报告期金额 | 年初至报告期期末 金额 | 说明 | | 非流动性资产处置损益（包括已计提资产减值准备的 | | 23,070.80 ...

东杰智能科技集团股份有限公司 2025 年第三季度报告 证券代码：300486 证券简称：东杰智能 公告编号：2025-140 一、主要财务数据 （一） 主要会计数据和财务指标 东杰智能科技集团股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度财务会计报告是否经过审计 □是 ☑否 1 东杰智能科技集团股份有限公司 2025 年第三季度报告 公司是否需追溯调整或重述以前年度会计数据 □是 ☑否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末比上 年初至报告期末 | | | --- | --- | --- | --- | --- | | | | 增减 | 年同期增减 | | | 营业收入（元） | 159,617,084.09 ...

厦门亿联网络技术股份有限公司 2025 年第三季度报告 证券代码：300628 证券简称：亿联网络 公告编号：2025-065 厦门亿联网络技术股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、董事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担 个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度财务会计报告是否经过审计 □是 否 1 厦门亿联网络技术股份有限公司 2025 年第三季度报告 一、主要财务数据 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 1,648,492,712.03 | 14.26% | 4,298,336,791.76 | 4.59% | | 归属于上市公司股东 ...

辽宁信德新材料科技（集团）股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 辽宁信德新材料科技（集团）股份有限公司 2025 年第三季度报告 证券代码：301349 证券简称：信德新材 公告编号：2025-051 1 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 辽宁信德新材料科技（集团）股份有限公司 2025 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末比上 年初至报告期末 | | | --- | --- | --- | --- | --- | | | | 增减 | 年同期增减 | | | 营业收入（元） | 332,306,038.87 | 62.40% | ...

云南罗平锌电股份有限公司 2025 年第三季度报告 证券代码：002114 证券简称：罗平锌电 公告编号：2025-057 云南罗平锌电股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会及董事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担 个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度财务会计报告是否经过审计 □是 否 1 云南罗平锌电股份有限公司 2025 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末比上 年初至报告期末 | | | --- | --- | --- | --- | --- | | | | 增减 | 年同期增减 | | | 营业收入（元） | 445,387,619.52 | 59.35% | 966, ...